[go: up one dir, main page]

AU2265701A - Anti-hiv-1 conjugates for treatment of hiv disease - Google Patents

Anti-hiv-1 conjugates for treatment of hiv disease

Info

Publication number
AU2265701A
AU2265701A AU22657/01A AU2265701A AU2265701A AU 2265701 A AU2265701 A AU 2265701A AU 22657/01 A AU22657/01 A AU 22657/01A AU 2265701 A AU2265701 A AU 2265701A AU 2265701 A AU2265701 A AU 2265701A
Authority
AU
Australia
Prior art keywords
hiv
conjugates
treatment
disease
hiv disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU22657/01A
Inventor
Michael Fung
David Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanox Inc
Original Assignee
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanox Inc filed Critical Tanox Inc
Publication of AU2265701A publication Critical patent/AU2265701A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU22657/01A 1999-12-16 2000-12-15 Anti-hiv-1 conjugates for treatment of hiv disease Abandoned AU2265701A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17118799P 1999-12-16 1999-12-16
US60171187 1999-12-16
PCT/US2000/034032 WO2001043779A2 (en) 1999-12-16 2000-12-15 Anti-hiv-1 conjugates for treatment of hiv disease

Publications (1)

Publication Number Publication Date
AU2265701A true AU2265701A (en) 2001-06-25

Family

ID=22622858

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22657/01A Abandoned AU2265701A (en) 1999-12-16 2000-12-15 Anti-hiv-1 conjugates for treatment of hiv disease

Country Status (2)

Country Link
AU (1) AU2265701A (en)
WO (1) WO2001043779A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003054017A2 (en) * 2001-12-21 2003-07-03 Micromet Ag Mono-and dual chemokine/cytokine constructs
EP1478738B1 (en) * 2002-02-22 2008-11-12 Progenics Pharmaceuticals, Inc. Anti-ccr5 antibody
RU2393872C2 (en) * 2004-08-30 2010-07-10 Шеринг Акциенгезельшафт Hiv-infection treatment by t-cell modulation
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
AU2007286451A1 (en) 2006-08-17 2008-02-21 F. Hoffmann-La Roche Ag A conjugate of an antibody against CCR5 and an antifusogenic peptide
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
EP2074147B1 (en) 2006-09-29 2012-03-21 F. Hoffmann-La Roche AG Antibodies against ccr5 and uses thereof
CL2008000707A1 (en) 2007-03-13 2008-09-22 Hoffmann La Roche CONJUGATE OF ANTIFUSOGENIC POLYPEPTIDES AND POLYPEPTIDES DERIVED FROM THE GLOBULAR HEAD OF THE COMPLEMENT FACTOR C1Q; PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT; ITS USE TO TREAT VIRIC INFECTIONS; AND PRODUCTION METHOD.
CL2008002092A1 (en) * 2007-07-20 2009-05-29 Hoffmann La Roche Conjugate containing two or more antifusogenic peptides and an anti-cd-4 antibody; Method of production; pharmaceutical composition comprising it; antifusogenic polypeptides and use of the conjugate to treat viral infections.
MX2011001583A (en) 2008-08-11 2011-04-04 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates.
WO2010028798A1 (en) * 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Multivalent antibodies
WO2010028797A1 (en) * 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Multivalent antibodies
WO2010028796A1 (en) * 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Trispecific hexavalent antibodies
WO2010028795A1 (en) * 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Multivalent antibodies
WO2010041241A2 (en) * 2008-10-06 2010-04-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Hiv-1 integrase derived peptides and compositions
RU2517084C2 (en) 2010-08-06 2014-05-27 Олег Ильич Эпштейн Method and means for inhibiting production or enhancing protein p24 elimination
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012166555A1 (en) 2011-05-27 2012-12-06 Nektar Therapeutics Water - soluble polymer - linked binding moiety and drug compounds
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
WO2016054296A2 (en) * 2014-09-30 2016-04-07 California Institute Of Technology Crosslinked anti-hiv-1 compositions for potent and broad neutralization
WO2016149695A1 (en) * 2015-03-19 2016-09-22 Duke University HIV-1 NEUTRALIZING ANTIBODIES AND USES THEREOF (CD4bs ANTIBODIES)
MA56222A (en) * 2015-04-24 2022-04-20 Viiv Healthcare Uk No 5 Ltd HIV FUSION TARGETING POLYPEPTIDES
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
CA3221152A1 (en) * 2021-06-10 2022-12-15 Marzena PAZGIER Antibody-cd4 conjugates and methods of using the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69126301T2 (en) * 1990-11-27 1998-01-02 Biogen, Inc., Cambridge, Mass. HIV-INDUCED SYNCYTIA BLOCKING ANTI-CD-4 ANTIBODIES
WO1998000535A2 (en) * 1996-06-28 1998-01-08 Dana-Farber Cancer Institute Method for inhibiting hiv-1 infection, drug screens, and methods of diagnosis and prognosis of susceptibility to hiv infection
AU731975B2 (en) * 1996-10-09 2001-04-12 Children's Medical Center Corporation GP120 polypeptides having conformational discontinuous chemokine receptor binding sites and methods of inhibiting HIV infection
DE19801265C1 (en) * 1998-01-15 1999-08-12 Deutsches Krebsforsch Inhibition of CD95-independent apoptosis in AIDS
CA2355607A1 (en) * 1998-12-16 2000-06-22 Progenics Pharmaceuticals, Inc. Anti-ccr5 antibody
AU2001243639A1 (en) * 2000-03-17 2001-10-03 Panacos Pharmaceuticals, Inc. A method for generating immunogens that elicit neutralizing antibodies against fusion-active regions of hiv envelope proteins

Also Published As

Publication number Publication date
WO2001043779A3 (en) 2002-05-10
WO2001043779A2 (en) 2001-06-21

Similar Documents

Publication Publication Date Title
AU2265701A (en) Anti-hiv-1 conjugates for treatment of hiv disease
AU2180400A (en) A pharmaceutical combination for the treatment of depression
AU2492600A (en) Surgical handpiece
AUPQ893200A0 (en) Medical residue treatment
AU6360400A (en) Ceramic dental mill blanks
AU4198500A (en) Suture-passing forceps
AU3469400A (en) Pharmaceutical compositions for treatment of diseased tissues
AU3009801A (en) Combinations of medicaments for treating viral diseases
AU2001265253A1 (en) Treatment of hiv using hyperthermia
AU5215300A (en) Dental treatment area
AU2495100A (en) Surgical handpiece
AU6715600A (en) Pharmaceutical formulations
AU7731700A (en) Low dose ifn-gamma for treatment of disease
AU2002219881A1 (en) Methods and compositions for the treatment of human immunodeficiency virus infection
AU2281601A (en) Treatment of viral infections using levovirinTM
AU7309900A (en) Anti-irritant disposable diaper
AU4977300A (en) Pharmaceutical formulations
AU1626101A (en) Human transcriptomes
AU4556800A (en) Novel treatment
AU1385801A (en) Pharmaceutical formulations
AU5394300A (en) Tissue engineering
AU3760900A (en) Treatment of menstrual function
AU7975500A (en) Drug for treatment of immunodeficiency states
AU1405001A (en) Treatment of diseases
AU2960000A (en) Detection of human immunodeficiency virus

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase